Incidence and prevalence of NMOSD in Australia and New Zealand

Wajih Bukhari, Kerri M. Prain, Patrick Waters, Mark Woodhall, Cullen M. O'Gorman, Laura Clarke, Roger A. Silvestrini, Christine S. Bundell, David Abernethy, Sandeep Bhuta, Stefan Blum, Mike Boggild, Karyn Boundy, Bruce J. Brew, Matthew Brown, Wallace J. Brownlee, Helmut Butzkueven, William M. Carroll, Celia Chen, Alan CoulthardRussell C. Dale, Chandi Das, Keith Dear, Marzena J. Fabis-Pedrini, David Fulcher, David Gillis, Simon Hawke, Robert Heard, Andrew P.D. Henderson, Saman Heshmat, Suzanne Hodgkinson, Sofia Jimenez-Sanchez, Trevor Killpatrick, John King, Christopher Kneebone, Andrew J. Kornberg, Jeannette Lechner-Scott, Ming Wei Lin, Christpher Lynch, Richard Macdonell, Deborah F. Mason, Pamela A. McCombe, Michael P. Pender, Jennifer A. Pereira, John D. Pollard, Stephen W. Reddel, Cameron Shaw, Judith Spies, James Stankovich, Ian Sutton, Steve Vucic, Richard C. Wong, Eppie M. Yiu, Michael H. Barnett, Allan G. Kermode, Mark P. Marriott, John D.E. Parratt, Mark Slee, Bruce V. Taylor, Ernest Willoughby, Robert J. Wilson, Angela Vincent, Simon A. Broadley

Research output: Contribution to journalArticlepeer-review

71 Citations (Scopus)
669 Downloads (Pure)


Objectives: We have undertaken a clinic-based survey of neuromyelitis optica spectrum disorders (NMOSDs) in Australia and New Zealand to establish incidence and prevalence across the region and in populations of differing ancestry. Background: NMOSD is a recently defined demyelinating disease of the central nervous system (CNS). The incidence and prevalence of NMOSD in Australia and New Zealand has not been established. Methods: Centres managing patients with demyelinating disease of the CNS across Australia and New Zealand reported patients with clinical and laboratory features that were suspicious for NMOSD. Testing for aquaporin 4 antibodies was undertaken in all suspected cases. From this group, cases were identified who fulfilled the 2015 Wingerchuk diagnostic criteria for NMOSD. A capture-recapture methodology was used to estimate incidence and prevalence, based on additional laboratory identified cases. Results: NMOSD was confirmed in 81/170 (48%) cases referred. Capture-recapture analysis gave an adjusted incidence estimate of 0.37 (95% CI 0.35 to 0.39) per million per year and a prevalence estimate for NMOSD of 0.70 (95% CI 0.61 to 0.78) per 100 000. NMOSD was three times more common in the Asian population (1.57 (95% CI 1.15 to 1.98) per 100 000) compared with the remainder of the population (0.57 (95% CI 0.50 to 0.65) per 100 000). The latitudinal gradient evident in multiple sclerosis was not seen in NMOSD. Conclusions: NMOSD incidence and prevalence in Australia and New Zealand are comparable with figures from other populations of largely European ancestry. We found NMOSD to be more common in the population with Asian ancestry.

Original languageEnglish
Pages (from-to)632-638
Number of pages7
JournalJournal of Neurology, Neurosurgery and Psychiatry
Issue number8
Publication statusPublished - 1 Aug 2017


Dive into the research topics of 'Incidence and prevalence of NMOSD in Australia and New Zealand'. Together they form a unique fingerprint.

Cite this